enoblituzumab
macrogenics
['enoblituzumab', 'prostate', 'biomarker']
targeting b7-h3 in #prostatecancer: phase 2 trial in localized #prostatecancer using the anti-b7-h3 antibody enoblituzumab, with biomarker correlatives. presented by . #asco22 coverage by &gt; 
Largest global online community of #urological medical professionals & patients. #AUA22 #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology